Authors: PATERSON, B. M.¹; LAMMERS, K. M.²; ARRIETA, M. C.³; FASANO, A.²; MEDDINGS, J. B.³

Source: Alimentary Pharmacology & Therapeutics, Volume 26, Number 5, September 2007 , pp. 757-766(10)

Publisher: Wiley-Blackwell

Abstract:

Summary Background

Lifelong adherence to a strict gluten-free diet is the cornerstone of coeliac disease treatment. Elucidation of disease pathogenesis has created opportunities for novel therapeutic approaches to coeliac disease. AT-1001 is an inhibitor of paracellular permeability whose structure is derived from a protein secreted by Vibrio cholerae. Aim

To determine the safety and tolerability of 12 mg doses of AT-1001 in coeliac disease subjects challenged with gluten. Methods

An in-patient, double-blind, randomized placebo-controlled safety study utilizing intestinal permeability, measured via fractional excretions of lactulose and mannitol, as an exploratory measure of drug efficacy. Results

Compared to placebo, no increase in adverse events occurred in patients exposed to AT-1001. Following acute gluten exposure, a 70% increase in intestinal permeability was detected in the placebo group, while none was seen in the AT-1001 group. Interferon-γ levels increased in four of seven patients (57%) of the placebo group, but only in four of 14 patients (29%) of the AT-1001 group. Gastrointestinal symptoms were more frequently detected in the placebo group when compared to the AT-1001 group (P = 0.018). Conclusions

AT-1001 is well tolerated and appears to reduce intestinal barrier dysfunction, proinflammatory cytokine production, and gastrointestinal symptoms in coeliacs after gluten exposure.

Document Type: Research article

DOI: http://dx.doi.org/10.1111/j.1365-2036.2007.03413.x

Affiliations: 1: Alba Therapeutics Corporation, Baltimore, MD, USA 2: Mucosal Biology Research Center and Center for Celiac Research, University of Maryland, School of Medicine, Baltimore, MD, USA 3: Department of Medicine, University of Alberta, Alberta, Canada

Publication date: 2007-09-01

Related content

• In this: publication
• By this: publisher
• In this Subject: Pathology ,  Pharmacology ,  Surgery ,  Therapeutics & Alternative Medicine
• By this author: PATERSON, B. M. ;  LAMMERS, K. M. ;  ARRIETA, M. C. ;  FASANO, A. ;  MEDDINGS, J. B.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers